SLS
SELLAS Life Sciences Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.49
+5.11%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$10.10
From 52W high−32.15%
Volume5.55M
Market cap$2.12B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$10.10
From 52W high
−32.15%
Volume
5.55M
Market cap
$2.12B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−78.0x
P/E (TTM)
—
RSI (14)
42.6
MomentumView details →
1D Return
+5.11%
YTD Return
+184.88%
SummaryUpdated Jun 1, 2026
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) is a late-stage biopharmaceutical company founded in 2012 and headquartered in New York, New York. The company went public in 2008 and focuses on developing novel cancer immunotherapies for various cancer indications. SELLAS operates as a clinical-stage biotechnology company with no current commercial products, dedicating its resources to advancing multiple cancer treatment candidates through clinical trials.
Similar companies
Latest newsMore news →
SELLAS Life Sciences presented preclinical data showing SLS009 (tambiciclib) activity in patient-derived organoid models of pancreatic ductal adenocarcinoma at the AACR Conference on Pancreatic Cancer in San Diego on September 25, 2026.24d agoSELLAS Life Sciences Group Inc. stock surged on Thursday, with a year-to-date gain of about 300%.53d agoSellas Life Sciences shares fell 7.66% to $14.28 on August 24, 2026, after a German media report speculated that the REGAL Phase 3 trial may have reached the 80th event needed for final analysis, but the company has not officially confirmed this, leaving retail investors skeptical.57d ago